株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

小児欠神てんかん(CAE)治療薬市場 - 市場規模、シェア、見通し、機会分析 2018年〜2026年

Childhood Absence Epilepsy Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026

発行 Coherent Market Insights 商品コード 754985
出版日 ページ情報 英文 144 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.05円で換算しております。
Back to Top
小児欠神てんかん(CAE)治療薬市場 - 市場規模、シェア、見通し、機会分析 2018年〜2026年 Childhood Absence Epilepsy Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026
出版日: 2018年12月04日 ページ情報: 英文 144 Pages
概要

小児欠神てんかんは、脳波検査(EEG)、ビデオによるテレメトリー、MRIスキャン、血液検査などによって診断されます。てんかんの構造的原因はMRIスキャンで明らかになりますが、てんかんの原因となる病気の存在を確認するために血液検査が必要になる場合もあります。

当レポートでは、世界の小児欠神てんかん(CAE)治療薬市場を調査し、市場の概要、治療薬・発作タイプ・地域別の市場規模の推移と予測、市場動向、市場シェア、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場概要

  • レポート概要
    • 市場定義と範囲
  • エグゼクティブサマリー
    • 市場スニペット:治療薬別
    • 市場スニペット:発作タイプ別
    • 市場スニペット:地域別
  • コヒーレントオポチュニティーマップ(COM)

第3章 市場力学、規制、動向分析

  • 小児欠神てんかん(CAE)について
  • 小児欠神てんかん(CAE)の診断
  • 治療法
  • 市場力学
    • 成長要因
    • 阻害要因
    • 市場機会
  • 規制シナリオ
  • パイプライン分析

第4章 世界の小児欠神てんかん市場:治療薬別

  • イントロダクション
  • エトスクシミド
  • バルプロエート
  • ラモトリギン
  • 第2相試験薬

第5章 世界の小児欠神てんかん市場:発作タイプ別

  • イントロダクション
  • 定型欠神発作
  • 非定型欠神発作

第6章 世界の小児欠神てんかん市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • アフリカ
  • 中東

第7章 競合情勢

  • ヒートマップ解析
  • 会社概要
    • Cavion, Inc.
    • Pfizer, Inc.
    • GlaxoSmithKline Plc
    • Insys Therapeutics, Inc.
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.

第8章 セクション

  • 参考文献
  • 調査方法
  • Coherent Market Insightsについて
目次

Childhood absence epilepsy diagnosis revolves around identifying symptoms and categorizing the epilepsy type based on those symptoms. Diagnostic methods and techniques for childhood absence epilepsy include electroencephalogram (EEG)/video telemetry, magnetic resonance imaging (MRI scans), and blood tests. In electroencephalogram (EEG)/video telemetry, electrical signals from brain are recorded in a computer by asking the patient to hyperventilate for 3 to 5 minutes, which triggers an absence seizure. The EEG then shows spikes and wave discharges at 3 Hz (cycles per second) that are generalized in nature (similar on both sides of the brain). Structural causes behind epilepsy can be understood with the help of MRI scans (as some patients suffering from epilepsy due to brain damage can be found by a MRI scan). Blood tests may be required to diagnose any medical conditions, which may be the reason behind epilepsy.

Market Dynamics

Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support growth of the market. For instance, Dr. Reddy's Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of childhood absence epilepsy treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2018-2026), considering 2016 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global childhood absence epilepsy treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
  • Key companies covered as a part of this study include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
  • The global childhood absence epilepsy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the childhood absence epilepsy treatment market

Detailed Segmentation:

  • Global Childhood Absence Epilepsy Treatment Market, By Drug:
    • Ethosuximide
    • Valproate
    • Lamotrigine
    • Phase 2 Drugs
      • Cannabidiol Oral Solution
      • CX-8998
  • Global Childhood Absence Epilepsy Treatment Market, By Disease Type:
    • Typical Absence Seizures
    • Atypical Absence Seizures
  • Global Childhood Absence Epilepsy Treatment Market, By Region:
    • North America
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
      • Cannabidiol Oral Solution
      • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
      • Cannabidiol Oral Solution
      • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
    • Cannabidiol Oral Solution
    • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
    • Cannabidiol Oral Solution
    • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
    • Cannabidiol Oral Solution
    • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug
      • Ethosuximide
      • Valproate
      • Lamotrigine
      • Phase 2 Drugs
    • Cannabidiol Oral Solution
    • CX-8998
      • By Disease Type:
      • Typical Absence Seizures
      • Atypical Absence Seizures
      • By Country:
      • Central Africa
      • South Africa
      • North Africa
  • Company Profiles
    • Cavion, Inc. *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Pfizer, Inc.
    • GlaxoSmithKline Plc
    • Insys Therapeutics, Inc.
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug
    • Market Snippet, By Disease Type
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • About Childhood Absence Epilepsy
  • Diagnosis of Childhood Absence Epilepsy
  • Treatment Approaches
  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Regulatory Scenario
  • Pipeline Analysis

4. Global Childhood Absence Epilepsy Treatment Market, By Drug, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Ethosuximide
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Valproate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Lamotrigine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Phase 2 Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
    • Cannabidiol Oral Solution
    • CX-8998

5. Global Childhood Absence Epilepsy Treatment Market, By Disease Type, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Typical Absence Seizures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)
  • Atypical Absence Seizures
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2026, (US$ Mn)

6. Global Childhood Absence Epilepsy Treatment Market, By Region, 2018-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2026
  • North America
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Drug, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2018-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2018-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

7. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Cavion, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Pfizer, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • GlaxoSmithKline Plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Insys Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • AbbVie, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top